Phase 1 N=55 Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0; 1; 4; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=367 A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival in Patients With Low High Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression — 5.7; 6.1 months — p=<0.973
Phase 2 N=20 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
Anal Cancer
Primary: 2 Year Failure Free Survival — 20 participants
Phase 1 N=960 Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
Infections, Papillomavirus
Primary: Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies — 5844.6; 10500.9; 7741.6; 13045.3 EL.U/mL
Phase 1 N=64 Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components
Healthy
Primary: AUC0-72 of Linagliptin — 278; 279 nmol*h/L
Phase 2 N=78 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
Influenza
Primary: Number of Seroconverted Subjects Against the H5N1 Strain of Influenza Disease. — 72 Participants
Phase 3 N=617 Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — -0.022; 0.125; 0.116 Liters — p=<0.001
N/A N=45 Zilver PTX Drug-Eluting Peripheral Stent Study
Peripheral Arterial Disease
Primary: Percent Change in Stent Length Upon Deployment — 0.5; -0.2 Change in stent length (%) — p=<0.01
N/A N=28 A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
Schizophrenia
Primary: BACS Composite RAW Score — 229.04; 227.83 units on a scale
N/A N=121 Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy
Smoking
Primary: Number of Participants Who Stopped Smoking by 6 Month Post Treatment — 18; 14 participants
Phase 3 N=274 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 8.2; 3.2 units on a scale — p=0.011
N/A N=251 Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years
Iron Deficiency
Primary: The Primary Outcome is Iron Depletion, and Will be Defined as Serum Ferritin <10 mcg/L. — 64; 71; 13; 10 participants — p=0.42
Phase 3 N=266 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 7.4; 5.7 units on a scale — p=0.68
N/A N=100 Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy
Laparoscopic Technique no Switch to Open · Duration of Surgery · Intraoperative Complications
Primary: Duration of Surgery — 75; 106 minutes
Phase 2 N=300 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Acute Undifferentiated Leukemia · B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg